Moreover, IL-6 is a representative cytokine in CAR-T cell-induced CRS, and the FDA has approved tocilizumab for the treatment of CRS after CAR T-cell therapy [148, 149]. The gene discussed is IL6; the disease is congenital rubella syndrome.